Faculty, Staff and Student Publications
Publication Date
8-1-2024
Journal
Advanced Healthcare Materials
DOI
10.1002/adhm.202302331
PMID
38359321
PMCID
PMC11324859
PubMedCentral® Posted Date
8-1-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Patient-derived organoids (PDOs) developed ex vivo and in vitro are increasingly used for therapeutic screening. They provide a more physiologically relevant model for drug discovery and development compared to traditional cell lines. However, several challenges remain to be addressed to fully realize the potential of PDOs in therapeutic screening. This paper summarizes recent advancements in PDO development and the enhancement of PDO culture models. This is achieved by leveraging materials engineering and microfabrication technologies, including organs-on-a-chip and droplet microfluidics. Additionally, this work discusses the application of PDOs in therapy screening to meet diverse requirements and overcome bottlenecks in cancer treatment. Furthermore, this work introduces tools for data processing and analysis of organoids, along with their microenvironment. These tools aim to achieve enhanced readouts. Finally, this work explores the challenges and future perspectives of using PDOs in drug development and personalized screening for cancer patients.
Keywords
Humans, Organoids, Neoplasms, Precision Medicine, Lab-On-A-Chip Devices, Drug Screening Assays, Antitumor, Patient-derived organoids, microfabrication technologies, therapeutic screening, cancer treatment, clinical translation
Published Open-Access
yes
Recommended Citation
Khorsandi, Danial; Yang, Jia-Wei; Foster, Samuel; et al., "Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients" (2024). Faculty, Staff and Student Publications. 5051.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5051
Graphical Abstract
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons